Q2 FY2026 EarningsQ2 FY26 results slightly beat revenue expectations ($1.01M vs. $0.96M) while GAAP Net Loss of $5.14M was narrower than the anticipated $6.18M. The primary focus is the $950M Moderna settlement, with the company receiving its $178.4M share in July 2026 and announcing plans to return up to $230M to shareholders. Alignment with the FDA on Phase 2b clinical trials for imdusiran provides a clear regulatory path forward, despite a significant YoY revenue decline due to the conclusion of the Qilu partnership.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Arbutus Pharma(ABUS) the Revenue is 994.49 K (-90.79%), Beat estimate;the EBIT is -5.849 M (-490.8%), Miss estimate;the EPS is -0.0294 (-392.5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B90.79%
0.00B93.74%
+0.00B2.95%
EBITMiss expectations
-0.01B490.75%
-0.01B442.36%
-0.00B48.39%
EPSMiss expectations
-0.0294392.54%
-0.019289.01%
-0.0104103.53%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf